Baxter International Inc. is an American multinational health care company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions.
| Revenue (TTM) | $11.32B |
| Gross Profit (TTM) | $3.92B |
| EBITDA | $1.91B |
| Operating Margin | 6.03% |
| Return on Equity | -15.00% |
| Return on Assets | 2.85% |
| Revenue/Share (TTM) | $22.03 |
| Book Value | $11.70 |
| Price-to-Book | 2.00 |
| Price-to-Sales (TTM) | 1.11 |
| EV/Revenue | 1.742 |
| EV/EBITDA | 26.30 |
| Quarterly Earnings Growth (YoY) | 237.90% |
| Quarterly Revenue Growth (YoY) | 2.90% |
| Shares Outstanding | $516.47M |
| Float | $513.99M |
| % Insiders | 0.34% |
| % Institutions | 106.19% |
Volatility is currently expanding
Medical product makers face Q2 margin pressure from tariffs and inflation even as demand stays strong. See which earnings reports could surprise.
BAX's second-quarter results may reflect pressured earnings and sales as manufacturing inefficiencies, inflation, and product holds offset steady demand across segments.
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Both AbbVie (NYSE:ABBV | ABBV Price Prediction) and Baxter International (NYSE:BAX) flashed the same technical signal this month: a golden cross, where the 50-day moving average pushed above the 200-day.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today published its newly renamed 2025 Sustainability Report, highlighting the company's progress and refreshed approach to advancing a sustainable and responsible business model. “As we shape Baxter's next chapter, our focus remains clear: making a meaningful difference for patients, customers and communities while working to create long‑term value for all stakeholders,” said Andrew Hider, presiden.
BAX gains as Synovis MCA signs a multi-year deal to commercialize MediThinQ's SHIYA 3D surgical visualization platform worldwide.
BAX is pursuing a broad turnaround as innovation, resilient demand, and AI integration support recovery despite regulatory risks and margin pressure.
Baxter International Inc. (BAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
In recent years, stocks like Baxter International have underperformed: most low-growth, high-debt, struggling names have been bad investments at basically any price. Concerns are real, and early missteps under new CEO Andrew Hider haven't helped. But valuation is attractive not just on an absolute basis but also relative to the outlook, and Q1 results seemed helpful to the bull case.
ICU Medical's new high-volume pump has more connected features, which we believe will drive retention rates and incremental revenue. SiteOne Landscape Supply controls 18% of this $26 billion industry and has been growing revenue at a low double-digit compound annual growth rate over the past several years. Madison Small Cap Fund liquidated its position in Globus Medical after a multi-year period because the company's success drove its market cap to $12B.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BAX and any ticker you trade — then tracks every position and per-strategy win rate.
